Drug Detail:Zoster vaccine recombinant (monograph) (Shingrix)
Drug Class:
Usual Adult Dose for Varicella-Zoster - Prophylaxis
0.5 mL intramuscularly
- Administer two doses, with the second dose given 2 to 6 months after the first dose
Comments:
- This drug is not indicated for prevention of primary varicella infection (chickenpox).
Uses: Prevention of herpes zoster (shingles) in:
- Adults aged 50 years and older
- Adults aged 18 years and older at increased risk of herpes zoster (HZ) due to immunodeficiency or immunosuppression from disease or therapy
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
- Severe allergic reaction (e.g. anaphylaxis) to any of the ingredients or after a previous dose of this vaccine
Safety and efficacy have not been established in patients younger than 18 years.
To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- For intramuscularly administration only.
- The preferred administration site is the deltoid region of the upper arm.
Storage requirements:
- Refrigerate; do not freeze
- Protect from light
- Discard if either component has been frozen.
Reconstitution/preparation techniques:
- Use only the diluent provided.
- Reconstituted product should be an opalescent, colorless to pale brownish liquid.
- Discard if particulate matter or discoloration are present after reconstitution.
- Administer immediately after reconstitution, or refrigerate between 36 and 46F and use within 6 hours.
